Insight Molecular Diagnostics Inc. (IMDX)
IMDX trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.99
-5.68% on the day
Market cap
$97.8M
Micro cap
Revenue · 2025
$4.1M
+115.6% on 2024
Net income · 2025
-$50K
-1.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | IMDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001642380 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | CA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.1M |
| Net income | -$50K |
| Operating income | -$51.1M |
| Net margin | -1.2% |
| Operating margin | -1260.8% |
| Revenue growth | +115.6% |
| Cash | $11.6M |
| Total assets | $25.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 24.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-11 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-08-10 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 688 recent filings. All filings on EDGAR.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
| TKNO | Alpha Teknova Inc. | $8.22 | -5.52% | $441.3M |
| NNNN | Anbio Biotechnology | $4.26 | -3.40% | $613.0M |
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| BMRA | Biomerica Inc. | $1.85 | +0.82% | $8.5M |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier